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Background: Stimulation of CD40 can augment anti-cancer T cell immune responses by triggering effective activation
and maturation of antigen-presenting cells (APCs). Although CD40 agonists have clinical activity in humans, the
associated systemic activation of the immune system triggers dose-limiting side-effects.
Methods: To increase the tumor selectivity of CD40 agonist-based therapies, we developed an approach in which
soluble trimeric CD40L (sCD40L) is genetically fused to tumor targeting antibody fragments, yielding scFv:CD40L fusion
proteins. We hypothesized that scFv:CD40L fusion proteins would have reduced CD40 agonist activity similar to sCD40L
but will be converted to a highly agonistic membrane CD40L-like form of CD40L upon anchoring to cell surface
exposed antigen via the scFv domain.
Results: Targeted delivery of CD40L to the carcinoma marker EpCAM on carcinoma cells induced dose-dependent
paracrine maturation of DCs ~20-fold more effective than a non-targeted control scFv:CD40L fusion protein. Similarly,
targeted delivery of CD40L to the B cell leukemia marker CD20 induced effective paracrine maturation of DCs. Of note,
the CD20-selective delivery of CD40L also triggered loss of cell viability in certain B cell leukemic cell lines as a result of
CD20-induced apoptosis.
Conclusions: Targeted delivery of CD40L to cancer cells is a promising strategy that may help to trigger
cancer-localized activation of CD40 and can be modified to exert additional anti-cancer activity via the targeting domain.
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The tumor necrosis factor (TNF) receptor family mem-
ber CD40 is a critical regulator of cellular and humoral
immunity. In line with this, CD40 is broadly expressed
on immune cells, although predominantly on antigen-
presenting cells (APCs) such as dendritic cells (DC) and
B cells [1-3]. One of the main functions of the CD40L/
CD40 system is to activate and “license” DCs to prime
effective cytotoxic CD8+ T cell responses [4,5]. In brief,
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article, unless otherwise stated.engages CD40 on APCs and induces APC activation
and maturation. In turn, such CD40-licensed APCs in-
duce activation and proliferation of antigen-specific
CD8+ cytotoxic T cells [6,7]. In the absence of CD40 sig-
nalling, the interaction of CD8+ T cells with so-called
“unlicensed” APCs induces T cell anergy or triggers forma-
tion of regulatory T cells [8]. Thus, CD40 is crucial for ef-
fective generation of cytotoxic CD8+ T cell immune
responses. Although normally induced by helper T
cells, CD40 signalling on APCs can also be effectively
triggered using agonistic antibodies or CD40L, thus
bypassing the need for CD4+ T cell help [4,9]. These
features delineate a clear rationale for CD40 agonist-
based cancer immunotherapy.
CD40 has been explored as a target for the treatment
of several forms of cancer using recombinant solubletral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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(Abs). In pre-clinical models, sCD40L and agonistic CD40
Abs are highly effective at inducing DC maturation and
eradicating tumors (reviewed in [4]). However, an import-
ant concern for this type of immunotherapy in humans is
the potential for systemic over activation of the immune
system and concomitant toxicity. Indeed, dose-limiting tox-
icity using sCD40L or agonistic CD40 antibodies has been
reported in humans [10-12]. Importantly, whereas systemic
treatment with agonistic CD40 Abs in pre-clinical mouse
models was associated with significant liver toxicity, local
administration of agonistic CD40 Abs proved equally effect-
ive, yet without the associated toxicity [13,14].
The efficacy of CD40 signaling is dependent on the
clustering of CD40 within the membrane of the targeted
cells. For instance, CD40-signaling induced by soluble
CD40L (sCD40L) was potentiated ~10-fold upon sec-
ondary cross-linking of CD40L into higher order multi-
mers [15-17]. In line with this, CD40 signaling induced
by anti-CD40 antibodies critically depends on the pres-
ence of Fc-receptor positive cells [18]. Based on these
crosslinking requirements for CD40/CD40L signaling,
CD40L has also been evaluated in a proof-of-concept
study with a fibroblast activation protein (FAP)-targeted
scFv:CD40L fusion protein. In brief, antibody fragment-
mediated anchoring to FAP-expressing cells enabled the
scFv:CD40L fusion protein to trigger IL-8 production in
target cells with an ~25-fold lowered ED50 value [17].
Here, we further developed this targeted approach by
evaluating the selective delivery of sCD40L to the well-
established carcinoma marker EpCAM and the B-cell
leukemia marker CD20. In brief, the resultant scFv:CD40L
fusion proteins were designed to selectively deliver sCD40L
to the cell surface of target antigen-positive cancer cells,
thereby triggering target antigen-restricted DC maturation
(see Figure 1 for schematic representation of the scFv:
CD40L fusion proteins). Second, the anti-CD20 antibody
fragment derived from rituximab has previously been
shown to trigger CD20 cross-linking dependent apoptosis
in B-cell leukemic cells in a scFv:FasL fusion protein [19].
Therefore, CD20 cross-linking by scFvCD20:CD40L
may trigger apoptotic elimination of malignant B-cells.
Both fusion proteins were evaluated for target cell-
selective activity as determined by auto- and paracrine
activation of antigen presenting cells (APCs) and scFv-
mediated anti-tumor effects.
Results
Antibody fragment-specific binding of scFv:CD40L
fusion proteins
To determine the binding characteristics of anti-
EpCAM:CD40L, the EpCAM-negative cell line HEK293
and the EpCAM-transfectant cell line HEK293.EpCAM
were incubated with anti-EpCAM:CD40L and analyzedfor CD40L by flow cytometry. Incubation of EpCAM-
negative HEK293 cells with anti-EpCAM:CD40L did not
trigger an increase in fluorescence upon anti-CD40L
antibody staining (Figure 2A; left panel). By contrast, in-
cubation of HEK293 cells engineered to express EpCAM
(HEK.EpCAM) with anti-EpCAM:CD40L resulted in a sig-
nificant increase in surface CD40L staining (Figure 2A;
right panel). As with HEK293, anti-EpCAM:CD40L did not
bind HEK293 cells that only expressed the intracellular do-
main of EpCAM (HEK293.EpICD; Figure 2A; middle
panel). Further, incubation of the EpCAM+ colon carcin-
oma cell line DLD-1 with anti-EpCAM:CD40L showed
a strong anti-CD40L fluorescence signal (Figure 2B; left
panel) that was completely inhibited by pre-incubation
with an epitope-competing EpCAM-blocking antibody
(Figure 2B, middle panel). Similar antibody fragment-
selective binding characteristics were obtained for the
anti-CD20:CD40L fusion protein, with selective binding
to CD20+ B cells (Figure 2C; left panel) that could be
inhibited with the parental mAb rituximab (Figure 2C;
middle panel). Furthermore, anti-CD20:CD40L failed to
bind to CD20− Jurkat T cells (Figure 2C; right panel).
Taken together, these data demonstrate that the scFv:
CD40L fusion proteins have a high binding affinity for
their respective target antigens EpCAM and CD20.
CD40L remains biologically active within scFv:CD40L
fusion proteins
To verify that N-terminal fusion of an scFv antibody frag-
ment to sCD40L did not negatively affect the biological
activity of the trimeric sCD40L, the capacity of scFv:
CD40L fusion proteins to induce DC-maturation was
assessed using anti-EpCAM:CD40L. Of note, non-targeted
sCD40L has previously been shown to induce DC-
maturation at relatively high concentrations ranging from
1 to 3 μg/ml [20]. Therefore, monocyte-derived immature
dendritic cells (iDCs) were treated with high concentra-
tions of the scFv:CD40L proteins (1 μg/ml) and analyzed
for induction of DC maturation markers (Additional file 1:
Figure S1A for protocol). Monocyte-derived iDCs had a
typical DC morphology and expressed low cell surface
levels of CD80 and CD86, intermediate levels of CD40
and HLA-DR, and lacked expression of CD83, a marker
for mature DCs (mDC) (Figure 3A). Treatment of iDC
with anti-EpCAM:CD40L dose-dependently increased the
percentage of CD80high/CD86high DCs (Figure 3B) and sig-
nificantly up-regulated HLA-DR expression (Figure 3C).
Importantly, the HLA-DRhigh but not the HLA-DRlow
DCs also expressed the mDC markers CD83 and CCR7
(Figure 3D; histograms and MFI for all markers in
Figure 3E and Additional file 1: Figure S1B, respectively)
and retained a CD14-negative phenotype (Additional file 1:
Figure S1C). These changes were in line with the pheno-
typic changes observed after treatment of iDC with
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Figure 1 Domain architecture and affinity purification of a scFv:CD40L fusion proteins. A ScFv:CD40L fusion proteins comprise a single
chain variable fragment (scFv) of the specificity of interest genetically linked to the extracellular domain of CD40L (amino acids 116–261) and a
FLAG-tag for affinity purification. Following production in eukaryotic cells, scFv:CD40L fusion proteins form stable homotrimeric fusion proteins.
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ger of DC maturation (Additional file 1: Figure S1D).
In line with this maturation marker profile, anti-
EpCAM:CD40L induced significant production of
the pro-inflammatory DC cytokine IL-12 after 3 days,
whereas untreated iDC produced negligible levels of IL-
12 (Additional file 1: Figure S1E).
Next, the anti-EpCAM:CD40L-matured DCs were an-
alyzed for their capacity to induce T cell proliferation in
allogeneic PBMCs. Hereto, allogeneic PBMCs were la-
beled with CFSE and mixed with DCs at the indicated
ratios, whereupon T-cell proliferation in mixed cultures
of iDC/PBMC and anti-EpCAM:CD40L matured DCs/
PBMCs was analyzed after 7 days. In these mixed cul-
tures, anti-EpCAM:CD40L matured DCs proved more po-
tent at inducing T cell proliferation than iDC (exemplary
proliferation plots in Figure 3F, quantified in Figure 3G),
with a significant increase in the percentage of proliferat-
ing T cells (Figure 3H). Taken together, these data demon-
strated that the soluble CD40L domain in scFv:CD40L
fusion proteins remains biologically active and, in corres-
pondence with its mode of action as a soluble molecule,
requires high concentrations over prolonged periods of
time to trigger efficient CD40 responses.
Cell surface-immobilization of CD40L on cancer cells
augments paracrine maturation of iDC
To evaluate whether target antigen-selective immobilization
of scFv:CD40L would augment CD40 signaling,
EpCAM−CD40− HT1080 cells and CD40-transfected
HT1080 cells (HT1080.CD40) were co-cultured with
EpCAM+/CD40− DLD-1. Subsequently, induction ofCD40 signaling was analyzed by measuring IL-8 produc-
tion. Treatment of HT1080.CD40 with anti-EpCAM:
CD40L triggered IL-8 at higher doses of 100–1000 ng/ml,
in line with the activity profile of sCD40L (Figure 4A; left
panel). However, in co-cultures of HT1080.CD40 with
EpCAM+ DLD-1 cells, the treatment with anti-EpCAM:
CD40L resulted in IL-8 secretion at significantly lower
doses, corresponding to a ~20-fold down-shift in the ED50
value (Figure 4A; middle panel). In mixed cultures of paren-
tal HT1080 with DLD-1 cells, no IL-8 secretion was de-
tected (Additional file 1: Figure S1F).
To subsequently assess the potentiating effect of targeted
delivery of CD40L on DC maturation, monocyte-derived
iDC were co-cultured with HEK293.EpCAM and overnight
production of IL-12 was determined as read-out for iDC
maturation. Monocultures of HEK293.EpCAM and iDCs
treated with increasing concentrations of anti-EpCAM:
CD40L did not produce IL-12 even at 1 μg/mL (Figure 4B:
left panel). By contrast, in iDC/HEK.EpCAM co-cultures,
treatment with anti-EpCAM:CD40L dose-dependently in-
duced IL-12 production (Figure 4B: middle panel). IL-12
production was dependent on EpCAM-specific binding
since pre-incubation with the parental EpCAM blocking
antibody largely blocked IL-12 production (Figure 4B: right
panel). In control mixed cultures of iDC with HEK.YFP
and HEK.EpICD only marginal levels of IL-12 were detect-
able (Figure 4B: middle panel). Furthermore, in co-culture
experiments of iDCs with a panel of EpCAM+ cancer cell
lines, treatment with anti-EpCAM:CD40L induced signifi-
cant IL-12 production that was inhibited by the EpCAM
blocking antibody (Figure 4C). By contrast, no IL-12 was de-
tected upon treatment of co-cultures of iDCs and EpCAM−
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Figure 2 Target antigen-restricted binding by scFv:CD40L fusion proteins. A HEK.YFP, HEK.EpICD-YFP, HEK.EpCAM-YFP or B DLD-1 and HT1080
cells were incubated with anti-EpCAM:CD40L for 1 h, washed 3 times with PBS and binding assessed by flow cytometry using a PE-conjugated
anti-CD40L antibody. To determined specific binding, cells were pretreated with parental anti-EpCAM antibody as indicated. C Raji B cells or Jurkat
T cells were incubated with anti-CD20:CD40L for 1 h, washed 3 times with PBS and binding assessed by flow cytometry using a PE-conjugated
anti-CD40L antibody. To determined specific binding, cells were pretreated with parental anti-CD20 antibody rituximab as indicated.
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http://www.molecular-cancer.com/content/13/1/85cancer cell lines with anti-EpCAM:CD40L (Figure 4C),
nor when EpCAM+ cells were treated with an scFv:CD40L
fusion protein of irrelevant specificity (Additional file 1:
Figure S1G).
In line with this IL-12 production, treatment of co-
cultures of iDC and HEK.EpCAM-YFP with anti-EpCAM:
CD40L also triggered phagocytic uptake of high numbers
of HEK.EpCAM cells (Figure 4D), whereas no such phago-
cytic uptake was detected in co-cultures with HEK or HEK.
EpICD cells (Figure 4D). Next, we assessed whether these
findings extended to DC-induced T cell proliferation. To
this end, we co-cultured a panel of five EpCAM+ cancer
cell lines with iDCs and allogeneic T cells in the presenceor absence of anti-EpCAM:CD40L using a modified pro-
cedure of the proliferation assay described above. Import-
antly, in 4 out of 5 cells lines, treatment with anti-EpCAM:
CD40L was associated with increased T cell proliferation
(Figure 4E).
Targeted delivery of CD40L to CD20 induces paracrine
maturation of dendritic cells
To assess whether these effects could be extended to
leukemic cancer cells, we next investigated the anti-CD20:
CD40L fusion protein. Similar to the effects observed for
anti-EpCAM:CD40L, monocultures of iDCs treated with
increasing concentrations of anti-CD20:CD40L only
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Figure 3 (See legend on next page.)
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Figure 3 CD40L remains biologically active in the context of scFv:CD40L fusion proteins. A Phenotypical and morphological characterization
of monocyte-derived DC (moDC) used for the study. After induction, moDC were harvested, stained with PE-conjugated antibodies specific for CD40,
CD80, CD83, CD86 and HLA-DR, and expression of the indicated molecules assessed using fluorescent microscopy. B-D Immature moDC were treated
for 3 days as indicated and cells with high levels of co-expressed CD80 and CD86 quantified using flow cytometry (B). In parallel, the expression of
CD83 and CCR7 was assessed in HLA-DRhigh and HLA-DRlow cells (C-D). E Representative flow cytometric plots of CD80, CD86, HLA-DR, CCR7 and CD83
expression on moDC matured for 3 days with 1 μg/mL anti-EpCAM:CD40L. F iDC and anti-EpCAM:CD40L-matured DC (1 μg/mL) were co-cultured with
1x105 CFSE-labeled allogeneic CD3+ T cells at the indicated cell numbers. T cell proliferation was determined by assessing loss of CFSE. G iDC were
matured using the indicated concentrations of anti-EpCAM:CD40L and allogeneic T cell proliferation assessed as described. H Representative CFSE
profiles of the experiment performed in G.
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http://www.molecular-cancer.com/content/13/1/85produced marginal levels of IL-12 (Figure 5A). By
contrast, in co-cultures of iDC with the CD20+ cell line
BJAB, treatment with anti-CD20:CD40L dose-dependently
induced IL-12 production (Figure 5A). IL-12 production
was dependent on CD20-binding since pre-incubation
with the parental CD20 blocking antibody rituximab fully
abrogated the increased IL-12 production (Figure 5A). In
control mixed cultures of iDC with CD20− Jurkat stimu-
lated with anti-CD20:CD40L, only marginal levels of IL-12
were detected (Figure 5B). These findings were extended
to the B cell leukemic lines Mino, Jeko and Daudi with
BJAB serving as positive control (Figure 5C). Treatment of
iDC:B cell co-cultures with either 30 or 300 ng/mL anti-
CD20:CD40L induced dose-dependent production of IL-
12 across all cell lines. As before, rituximab fully abrogated
the induction of IL-12, indicating a CD20-dependent ef-
fect. Of note, treatment of B cell lines or iDC alone in-
duced no or only marginal production of IL-12 in these
experiments (Figure 5C).
Targeted delivery of CD40L to leukemic cell lines induces
non-proliferative CD40 signaling
In leukemic cells, signaling via CD40 has been linked to
both pro-survival and anti-cancer effects [21,22]. How-
ever, most of these studies have been performed using
varying CD40-targeted agents (e.g. crosslinked CD40L
or antibodies), complicating interpretation. Therefore,
to assess the direct effects of anti-CD20:CD40L on
leukemic B cells, BJAB and Raji were treated for 3 days
with increasing concentrations of anti-CD20:CD40L
and changes in cell surface expression of B cell matur-
ation markers were assessed. In these experiments, the
optimal dose for non-saturating induction of signaling
was determined at 250 ng/mL (not shown). In both cell
lines, treatment with anti-CD20:CD40L induced an in-
crease in cell surface CCR7 (Additional file 1: Figure
S1H and S1I), whereas no significant changes were ob-
served in the cell surface levels of HLA-DR, CD80 or
CD86 (Additional file 1: Figure S1H and S1I). Interest-
ingly, treatment with anti-CD20:CD40L induced an up-
regulation of CD83 on BJAB cells and a downregulation
of CD83 on Raji cells, indicating cell type-specific ef-
fects of CD40 signaling (Additional file 1: Figure S1H
and S1I). As expected, treatment of leukemic B cell lineswith control fusion protein anti-EpCAM:CD40L had no
effect in this setting even when applied at concentrations
up to 1 μg/mL (not shown). Finally, we did not observe
proliferation or cell death as a result of treatment with
anti-CD20:CD40L within this time frame (not shown).
scFv-mediated delivery of CD40L induces secondary
scFv-dependent effects in cancer cells
We previously demonstrated a synergistic anti-cancer ef-
fect by an anti-CD20 fusion protein that relied on simul-
taneous induction of 1. death receptor-mediated apoptosis
by FasL and 2. cell death via crosslinking of CD20 by the
Rituximab scFv [19]. Therefore, we assessed whether tar-
geted delivery of CD40L to CD20 by means of anti-CD20:
CD40L could likewise induce CD20-mediated cell death.
Treatment of leukemic B cell lines BJAB, Raji and Z138 in-
duced a significant loss of viable cells after 5d, similar to
that observed for treatment with rituximab (Figure 6A-C).
Treatment of cells with anti-EpCAM:CD40L had no appar-
ent effects at concentrations up to 1 μg/mL (Figure 6A-C).
Of note, induction of cell death by rituximab occurred
only in the presence of a secondary crosslinker, whereas
anti-CD20:CD40L-induced cell death did not require
oligomerization. These findings are in agreement with the
data on anti-EpCAM:CD40L and suggest a model where
binding of anti-CD20:CD40L to the cell surface induces
CD40-clustering and concomitant crosslinking of CD20.
Discussion
We explored targeted delivery of CD40 ligand to the
cancer cell-surface as a therapeutic option for treatment
of malignancies. To this end, we generated EpCAM- and
CD20-targeted fusion proteins, anti-EpCAM:CD40L and
anti-CD20:CD40L, respectively, and analyzed functional
immune parameters. Based on our findings, CD40L re-
mains biologically active in scFv fusion proteins, with an
activity profile similar to soluble CD40L. However, binding
of CD40L fusion proteins to target antigens on the cancer
cell surface promotes oligomerization and augmented acti-
vation of CD40 on neighboring immature DC. As a result,
maturation of iDC occurred at approximately 20 fold
lower concentrations as in the case of stimulation with
“unbound” CD40L. In addition, we describe how targeted
delivery of CD40L to CD20+ leukemic B cells can induce
B
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Figure 4 EpCAM-restricted paracrine maturation of immature DC by anti-EpCAM:CD40L. A Indicated mono- and/or co-cultures of
HT1080, HT1080.CD40 and DLD-1 were treated with increasing concentrations of anti-EpCAM:CD40L and CD40 signaling assessed by measuring
production of IL-8. B Indicated mono- and co-cultures of HEK.YFP, HEK.EpICD-YFP, HEK.EpCAM-YFP and immature moDC (iDC) were treated overnight
with increasing concentrations of anti-EpCAM:CD40L. iDC maturation was assessed by determining the concentration of IL-12/23 in the culture
supernatant. To determine antigen-dependent effects, cells were pre-treated with parental anti-EpCAM blocking antibody. C iDC were co-cultured
overnight with the indicated tumor cell lines in the presence or absence of 100 ng/mL anti-EpCAM:CD40L ± anti-EpCAM blocking antibody.
iDC maturation was assessed by determining the concentration of IL-12/23 in the culture supernatant. D HEK293.YFP, HEK293.EpICD-YFP or
HEK293.EpCAM-YFP cells were co-cultured for 2 h with iDC at a 1:1 ratio in the presence or absence of anti-EpCAM:CD40L. Phagocytosis by the
CD80high/CD86high population was determined using flow cytometry. E iDC were co-cultured for 3 days with the indicated tumor cell lines in
the presence or absence of anti-EpCAM:CD40L. Co-cultures were harvested, inactivated and replated at the indicated ratio with PBMCs. T cell
proliferation was assessed 6 days later as described.
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http://www.molecular-cancer.com/content/13/1/85simultaneous B cell death and paracrine maturation of
iDC. Importantly, B cell lines did not undergo additional
proliferation as a result of treatment with anti-CD20:
CD40L. These findings are in agreement with earlier re-
ports on therapeutic exploitation of CD40 and highlight
our approach as a means of achieving loco-regional mat-
uration of DC in the tumor micro-environment [13]. Fur-
thermore, rational incorporation of scFv fragments into
these fusion proteins can be used to confer additional
anti-cancer effects.A
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http://www.molecular-cancer.com/content/13/1/85constitutively inducing ligand oligomerization to optimize
signaling activity could promote off-target systemic tox-
icity, cell surface immobilization can “open” the thera-
peutic window.
This might also be of relevance for therapies that base
on CD40 activation. Both pre-clinical and clinical studies
have highlighted toxicity concerns with the use of agon-
istic CD40-targeted agents for treating cancer [10,11,26].
Indeed, in the first clinical trials with the agonistic anti-
CD40 antibody CP-870,893, grade 1 to 2 toxicities in the
form of cytokine release syndrome were observed in
~55% of patients and two grade 3 toxicities out of 27 pa-
tients were reported. Nevertheless, 4 out of 27 patients
had a partial response indicating the potential of target-
ing CD40 [10]. Similarly, 2 out of 32 patients adminis-
tered soluble recombinant human CD40L (rhCD40L)
displayed signs of a partial response, although treatment
was associated with transient elevations of serum liver
transaminases (grade 3 or 4 severity) in 28% of the pa-
tients treated with the maximum tolerated dose (MTD;
of 0.1 mg/kg) [27]. Of note, these transient signs of liver
toxicity have also frequently been reported in preclinical
work on CD40-targeted therapeutics (discussed in [13].
To overcome these toxicity issues in the preclinical
setting, the group of Melief et al. has previously evalu-
ated a local release strategy for immunomodulatory anti-
bodies [14]. In their approach, an anti-CD40 antibody is
dissolved in a slow release formulation of the adjuvant
Montanide and injected near the tumor site. After this
loco-regional application, the antibody is proposed to
drain into the lymphatic system and (re-)activate resi-
dent DCs to mount an anti-tumor immune response.
Since DC in the draining nodes are exposed to tumor
associated antigens, a systemic immune response is in-
duced that could eradicate contra lateral tumor masses
in these animals. Importantly, this approach was associ-
ated with significantly reduced liver toxicity compared tosystemic injection, and allowed for much higher local
dosage. Nevertheless, loco regional application remains
unfeasible for most cancers.
In our targeted approach, we expect to achieve a similar
therapeutic efficacy as local release with the advantage of
systemic application (Figure 7). As mentioned, the scFv:
CD40L is anticipated to be largely inactive “en route” to
the cancer cells by virtue of 1. the higher affinity of the
scFv for the tumor antigen compared to CD40L for CD40
and 2. due to the limited signalling activity of soluble
CD40L. Indeed, binding of CD40L to CD40 in our flow
cytometric experiments was weaker compared to antigen-
mediated binding. To reduce off target effects, rational se-
lection of a target antigen is therefore a key factor in
design of such therapeutics. Here, we chose EpCAM to
target CD40L to the cell surface of epithelial cancer. In
normal epithelia, EpCAM is thought to be shielded by an
intact basal lamina, thereby preventing binding and accu-
mulation of the anti-EpCAM:CD40L fusion protein on
untransformed cells [28-30]. During malignant transform-
ation, polarity is lost and EpCAM exposed to antibody-
based therapeutics.
For targeting B cells, we chose the antigen CD20. CD20
is expressed on both healthy and malignant B cells and
is a well-established target for therapy of B cell leukaemia
(i.e. Rituximab) [31,32]. CD20-targeted therapeutics are
generally well tolerated and transient depletion of healthy
B cells can be clinically managed [31,32]. However, care
should be taken with targeted delivery of CD40L for treat-
ment of B cell malignancies as several studies have dem-
onstrated a role for CD40 in promoting progression of
malignancies, and antagonistic anti-CD40 antibodies have
met with clinical success in the treatment of certain haem-
atological cancers [21,22,33]. Nevertheless, in line with
earlier findings we observed no growth or survival pro-
moting effects of anti-CD20:CD40L on leukemic B cells at
doses up to 1 μg/mL and/or extended 5 day treatment.
EpCAM
anti-EpCAM:CD40L
immature DC
CD40
maturation
mature DC
upregulation of MHC-II
migration to draining lymph node
T-cell activation
MHC-restricted
tumor cell
elimination
Figure 7 Schematic representation of the proposed mode of action for scFv:CD40L fusion proteins; exemplified for anti-EpCAM:CD40L.
Binding of anti-EpCAM:CD40L to EpCAM+ target cancer cells induces paracrine CD40 signaling in tumor resident immature dendritic cells (iDC).
Subsequent maturation of iDC results in migration to draining lymph nodes and upregulation of antigen-presenting and co-stimulatory
molecules. Mature DC (mDC) can subsequently induce specific T cell activation and anti-tumor immunity.
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http://www.molecular-cancer.com/content/13/1/85However, we cannot exclude the possibility that concur-
rent signalling via CD20 abrogates the proliferative aspects
that are normally observed with activation of CD40. In-
deed, crosslinking of CD20 via the rituximab-derived anti-
CD20 scFv induced a potent loss of cell viability in a subset
of leukemic B cells.
Conclusions
We describe how targeted delivery of CD40L to cancer an-
tigens can be exploited to achieve localized activation of
CD40 and can be modified to exert additional anti-cancer
action via the targeting domain. To our knowledge, this is
first report of antigen-restricted maturation of antigen
presenting cells by CD40L. Further studies should aim to
elucidate whether this approach can be used to improve
the anti-tumor efficacy and safety profile of CD40 activa-
tion in vivo.Materials & methods
Plasmids
Expression vectors encoding the Flag-tagged CD40 ligand
are derived from a variant of pCR3 (Invitrogen), which
was provided by P. Schneider (University of Lausanne,
Epalinges, Switzerland) and encodes an Ig signal peptide
followed by a Flag tag. To obtain scFvRit:CD40L (anti-
CD20:CD40L), amplicons of CD40L encoding amino acids
116–261 including a stop codon were first inserted in
frame 5’ to the Flag tag by standard cloning techniques.
Next, the leader encoding fragment of the Flag-ligand en-
coding plasmid was replaced by an amplicon encoding the
leader sequence plus the scFvRit cDNA as previously re-
ported [17]. scFvC54 (anti-EpCAM) was generated analo-
gously using PCR from vector pEE14-scFvC54:TRAIL and
inserted 5’ to the Flag tag as described above.Production and purification
ScFvRit:CD40L (anti-CD20:CD40L) and scFvC54:CD40L
(anti-EpCAM:CD40L) were produced in HEK293 cells by
transient transfection of the expression vector. In brief,
cells were electroporated (50 × 106 cells/ml, 4-mm cuvette,
250 V, 1800 μF, maximum resistance) with 30 μg of DNA
in 1 ml of culture medium containing 10% FCS using an
Easyject Plus electroporator (PeqLab). Electroporated cells
were recovered overnight in RPMI 1640 with 10% FCS
(PAA Laboratories), and the next day the medium was re-
placed by low serum RPMI 1640 (0.5% FCS). After 3–4
days supernatants were collected and clarified by centrifu-
gation. Fusion proteins were purified by affinity chroma-
tography on anti-Flag M2 agarose beads (Sigma-Aldrich)
and eluted with TBS containing 100 μg/ml Flag peptide
(Sigma-Aldrich). The fractions containing the recombin-
ant proteins were finally dialyzed against PBS, purity
assessed by gel electrophoresis (Figure 1B) and stored
at −20°C for further analysis.
Cell lines
OvCAR-3, HT-29, DLD-1, HCT-8, Sw480, Sw620, Caco-2,
HT1080, HEK293, A375M, 786-O, BJAB, Jurkat, Daudi,
Jeko and Mino were obtained from the American Tissue
Culture Collection (ATCC) and characterized by short tan-
dem repeat profiling, karyotyping and isoenzyme analysis.
HT1080.CD40 cells were generated as described before.
HEK293.YFP, HEK293.EpICD-YFP and HEK.EpCAM-YFP
were a kind gift from Dr. O. Gires (University of München)
[34]. Cells were cultured in RPMI 1640 medium supple-
mented with 10% fetal calf serum and 500 μg/ml Geneticin.
Isolation, cultivation, and stimulation of primary cells
Monocytes and PBMCs were isolated from rests of
blood buffy coats of fully anonymized donors obtained
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Hämotherapy of the University Hospital Würzburg and
required no special written informed consent. PBMCs
were isolated by density gradient centrifugation with
lymphocyte separation medium (PAA Laboratories) [35].
Monocytes were separated from PBMCs by MACS mag-
netic bead separation with anti-CD14-coated beads
(Miltenyi Biotec). Monocytes were seeded in 6-well plates
(3 × 106 cells) with RPMI 1640, 10% FCS, and penicillin/
streptomycin. For DC differentiation 100 ng/ml GM-CSF
and 20 ng/ml IL-4 (ImmunoTools) were added every sec-
ond day. On day 7, cells were stimulated as indicated. On
day 10, functional analyses were performed as indicated.
FACS analysis and fluorescent microscopy
To determine cell surface expression of the indicated
markers by flow cytometry, cells were incubated on ice
with anti-CD14-FITC, anti-CD80-PE, anti-CD83-FITC,
anti-CD86-APC, anti-CCR7-APC, anti-HLA-DR-PE and/
or indicated combinations thereof or the appropriate iso-
type control Abs (all from Becton Dickinson, Amsterdam,
The Netherlands). After three washes with ice-cold PBS,
cell-associated immunofluorescence was determined by
FACS analysis. For binding studies with the scFv:CD40L
constructs, indicated cell lines were incubated on ice for
1 h with scFv:CD40L fusion proteins, washed three times
with ice-cold PBS and stained with anti-CD40L-PE anti-
body (Becton Dickinson, Amsterdam, The Netherlands)
on ice for another 1 h. Subsequently, cells were washed
three more times with ice-cold PBS and used for flow cy-
tometry. For blocking studies, cells were pre-incubated
with control antibodies (Rituximab or MOC31-Fc) for 1 h
on ice prior to incubation with fusion protein.
For immunofluorescence, cells were washed and stained
with the indicated PE-conjugated antibodies (anti-CD40-
PE, anti-CD80-PE, anti-CD83-PE, anti-CD86-PE and anti-
HLA-DR-PE all from Becton Dickinson, Amsterdam, The
Netherlands) on ice. After three washes with ice-cold PBS,
cell-associated immunofluorescence was determined by
fluorescent microscopy. All fluorescent microscopy was
performed on an EVOS fl Digital Fluorescence Microscope.
ELISA analysis
Cancer cells were seeded (2 × 104 cells/well) in 96-well tis-
sue cultures plates in 100 μl of RPMI 1640 medium with
10% FCS and grown overnight. On the next day, medium
was exchanged to minimize the background of constitu-
tive cytokine production, and cells were stimulated for
16 h with the indicated concentrations of fusion protein ±
blocking antibody in the presence or absence of indicated
HT1080 transfectants or Dendritic cells. Supernatants
were analyzed for production of IL-8 or IL-12 using the
BD human IL-8 ELISA or IL-12/IL-23 Duoset ELISA (BD
Biosciences) according to the manufacturer’s instructions.T cell proliferation
Dendritic cells (DCs) matured as indicated (or relevant
controls) were harvested, washed three times and resus-
pended at a density of 1×107 cells/mL. DCs were subse-
quently incubated with 50 μg/mL Mitomycin C solution
in PBS (freshly prepared and filter sterilized at 0.5 mg/mL)
in the dark for 20 min. at 37°C. After incubation, Mitomy-
cin C was rapidly diluted by addition of an excess of warm
culture medium and cells were washed three more times
by centrifugation. Cells were resuspended at a density of
10×106 cells/mL and plated at the indicated densities/ra-
tios in round-bottom 96-well plates in the presence of
1×105 T cells/well. DC-T cell co-cultures were briefly cen-
trifuged (1 min, 100 g) to promote cell-cell contact, incu-
bated for 6 days at 37°C in a humidified 5% CO2 incubator
and T cell proliferation assessed by CFSE dilution on a
flow cytometer. For CFSE-labeling, the Vybrant® CFDA SE
Cell Tracer Kit (Invitrogen) was used according to the
manufacturer’s instructions. In all experiments, T cells au-
tologous to the Dendritic cell population were used as
control and never displayed >5% proliferation. For co-
cultures of dendritic cells and tumor cells this procedure
was slightly modified. First, the ratios used in co-culture of
immature dendritic cells and tumor cells were optimized
per cell line to prevent cancer cells from overgrowing. Sec-
ond, the percentage of viable dendritic cells within the
mixed population after 3 day maturation was assessed
using CD86/CD83/PI staining on flow cytometry and cell
counts adjusted accordingly to a PBMC/DC ratio of 32.
Of note, mitomycin C treatment did not fully abrogate
cancer cell growth during the 6 day MLR, but slowly pro-
liferating cancer cells did not affect T cell viability within
this time frame.
Phagocytosis
HEK293.YFP, HEK293.EpICD-YFP or HEK293.EpCAM-
YFP cells were harvested and kept in suspension. Cells
were added at a 1:1 ratio to cultures of iDC in the pres-
ence or absence of anti-EpCAM:CD40L for 2 h, washed
three times with ice cold PBS and stained with anti-
CD80 and anti-CD86 antibodies as described in the sec-
tion on flow cytometry. Cells were gated exclusively on
the single cell population by FSC/SSC analysis to ex-
clude DC:HEK cell doublets. DCs were identified based
on co-expression of CD80 and CD86 expression and the
increase in YFP signal assessed in the FL1 channel by
means of the indicated histograms. Percentages were de-
termined based on the amount of YFP+ cells within the
total CD80/CD86 population.
B cell maturation and cell death
Primary B cells were cultured for up to 5d as indicated
in 6-well plates (1×106 cells/well; 3 mL/well) in the pres-
ence or absence of the indicated concentrations of anti-
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specific maturation, binding of anti-CD20:CD40L was
blocked by pre- and subsequently co-incubating cells
with 10 μg/mL of parental antibody rituximab. Where
indicated, B cells were also treated with (Fab-fragment
crosslinked) Rituximab, an irrelevant IgG1 control, or
anti-EpCAM:CD40L, all at a final concentration of
1 μg/mL. B cell maturation was assessed by flow cy-
tometry as described above. Cell death in B cell lines
was evaluated by loss of mitochondrial membrane po-
tential (ΔΨ) using DioC6 according to the manufac-
turer’s instructions (Molecular Probes).
Statistical analysis
Data reported are mean values ± SD of at least three inde-
pendent experiments. Statistical analysis was performed by
one-way ANOVA followed by Tukey-Kramer post test or,
where appropriate, by two-sided unpaired Student’s t-test.
p < 0.05 was defined as a statistically significant difference.
Where indicated * = p < 0.05; ** = p < 0.01; *** = p < 0.001.
Additional file
Additional file 1: Figure S1. Schematic representation of the proposed
mode of action for scFv:CD40L fusion proteins; exemplified for anti-EpCAM:
CD40L. A Protocol for DC maturation and T cell proliferation used in this
study. B Mean fluorescent intensities (MFI) for the DC maturation markers
CD80, CD86, HLA-DR, CCR7, CD84 and CD40 as depicted in Figure 3C-E were
quantified from 4 independent experiments with different donors. C After
induction, immature moDC (iDC) and mature moDC (mDC) were harvested,
stained with FITC-conjugated antibody specific for CD14 and expression
assessed using flow cytometry. D iDC were treated for 72 h with 1 μg/mL
anti-EpCAM:CD40L or 1 μg/mL Lipopolysaccharide (LPS) and the percentage
of DC expressing CD86, CD83 or HLA-DR quantified by flow cytometry
(n = 3). E iDC were treated for 72 h with 1 μg/mL anti-EpCAM:CD40L
and production of IL-12/23 assessed by ELISA on the culture supernatant. F
Indicated mono- and co-cultures of HT1080, HT1080.CD40 and DLD-1 were
treated overnight with increasing concentrations of anti-EpCAM:CD40L.
CD40 signaling was assessed by determining the concentration of IL-8 in
the culture supernatant. G iDC were co-cultured overnight with HEK.EpCAM-
YFP cells and treated with increasing concentrations of anti-EpCAM:CD40L
or anti-CD20:CD40L. iDC maturation was assessed by determining the
concentration of IL-12/23 in the culture supernatant. H BJAB and I Raji B cell
leukemia lines were treated for 5d with anti-CD20:CD40L and maturation
assessed by flow cytometry using fluorescently-conjugated anti-CD80, CD86,
HLA-DR, CCR7 and CD83 specific antibodies.
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